EVT-101 free base – (627525-33-1)

EVT-101, also known as ENS-101, is an experimental medication under development by Evotec AG for the treatment of major depressive disorder. It functions as a selective NMDA receptor subunit 2B (NR2B) antagonist.

Originally originating from Roche, EVT-101 is currently in clinical trials, with its maximum phase being II. The compound exhibits a high affinity for the NR2B subunit of the NMDA receptor, which is believed to play a crucial role in the pathophysiology of depression.

Clinical trials have indicated that EVT-101 may offer a rapid onset of antidepressant effects without significant dissociative or psychotomimetic side effects, which are common with other NMDA receptor antagonists like ketamine. The drug’s development is part of a broader effort to explore non-monoaminergic pathways in the treatment of depressive disorders, highlighting the potential of glutamatergic agents in addressing treatment-resistant depression.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://pubchem.ncbi.nlm.nih.gov/compound/22240172
https://www.medkoo.com/products/31615
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.884155/full
https://www.sciencedirect.com/science/article/abs/pii/S0223523423002842